The Sleep Apnea Devices industry is set to grow from US$ 6.47 Billion in 2024 to an impressive US$ 12.23 Billion by 2033, at ...

Participants with untreated sleep disorder were nearly twice as likely to develop the neurodegenerative condition, according ...

That’s according to a new study led by Oregon Health & Science University and the Portland Veterans Affairs Health Care System, where researchers found that veterans with untreated obstructive sleep ...

New research reveals that people with untreated obstructive sleep apnea have a higher risk of developing Parkinson's disease.

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP ...

Those with the sleep condition were more likely to develop Parkinson’s disease. But one treatment was found to help.

Air Voel, one of Canada’s leading providers of CPAP machines, masks, and sleep-health solutions, today announced the launch of its Sleep Better 2026 Initiative, a nationwide program designed to raise ...

Let's see why these shares could be great long term picks for Aussie investors. The post 2 screaming buy ASX shares I'd hold ...

Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...